반응식
[NH2:1][C:2]1[CH:10]=[CH:9][CH:8]=[C:7]2[C:3]=1[CH:4]=[CH:5][N:6]2[CH2:11][C:12]1[CH:17]=[CH:16][N:15]=[C:14]2[N:18](C(OC(C)(C)C)=O)[CH:19]=[CH:20][C:13]=12.[Cl:28][C:29]1[CH:30]=[CH:31][C:32]([O:38][CH3:39])=[C:33]([N:35]=[C:36]=[O:37])[CH:34]=1>C(Cl)Cl>[ClH:28].[O:38]([C:32]1[CH:31]=[CH:30][C:29]([Cl:28])=[CH:34][C:33]=1[NH:35][C:36]([NH:1][C:2]1[CH:10]=[CH:9][CH:8]=[C:7]2[C:3]=1[CH:4]=[CH:5][N:6]2[CH2:11][C:12]1[CH:17]=[CH:16][N:15]=[C:14]2[NH:18][CH:19]=[CH:20][C:13]=12)=[O:37])[CH3:39]참가 물질
4
실험 절차
To a solution of 4-[(4-amino-1H-indol-1-yl)methyl]-1-(t-butyloxycarbonyl)-1H-pyrrolo[2,3-b]pyridine (450 mg) in DCM was added 5-chloro-2-methoxyphenyl isocyanate (Int-4, 275 mg, 1.5 mmol). The mixture was stirred overnight, then concentrated, and purified by flash column chromatography to give the desired product 1-(2-methoxyl-5-chlorophenyl)-3-{1-[1-(t-butyloxycarbonyl)-1H-pyrrolo[2, 3-1)]pyridin-4-ylmethyl]-1H-indol-4-yl}urea (540 mg, 80% for two steps).
후처리
- concentrationconcentrated
- custompurified by flash column chromatography
출처 및 근거
- ORD 기록
- ord-1ab44ff768a1481ba93feb2566b29bd7
- 출처 데이터셋
- uspto-grants-2014_02
- 특허 번호
- US08648086B2
연결된 노트
불러오는 중…